不同给药方案介入治疗原发性肝癌的临床疗效与安全性分析  

Clinical efficacy and safety analysis of interventional therapy with different medications for hepatocellular carcinoma

作　　者：鲍乐[1] 袁磊[1] 张辉[1] 郭爱军[1] 

机构地区：[1]江苏省徐州市肿瘤医院介入科,江苏徐州221000

出　　处：《中国现代医生》2016年第11期69-71,共3页China Modern Doctor

摘　　要：目的探讨不同给药方案介入治疗原发性肝癌（HCC）的临床疗效和安全性。方法选取60例HCC患者并随机分为观察组和对照组，其中对照组采用奥沙利铂联合吉西他滨经导管肝动脉化疗栓塞（TACE）治疗，观察组采用奥沙利铂联合表柔比星TACE治疗，4-6周为1个疗程，评价两组治疗的总有效率及不良反应情况。结果经介入治疗后，观察组患者总有效率明显高于对照组（P〈0．05）；观察组患者白细胞减少率、血小板减少率、中性粒细胞减少率均显著低于对照组（P〈0．05）。观察组患者的2年期生存率明显高于对照组（P〈0．05）。结论奥沙利铂联合表柔比星行TACE术治疗HCC取得较好的疗效，且不良反应发生率较低，远期疗效更优，值得深入研究和推广。Objective To investigate the clinical efficacy and safety of interventional therapy with different medications for hepatocellular carcinoma （HCC）. Methods A total of 60 patients were randomly divided into control group, which was given gemcitabine and oxaliplatin combined with TACE treatment, and observation group, which was treated with epirubicin plus oxaliplatin combined with TACE treatment. The efficacy of treatment and side effects were compared between the two groups. Results Total effective rate in the observation group was lower than that in the control group （P〈0.05）. Reduction rates of the leukocyte, platelet and neutrophil granuloeyte in the observation group were higher than those in the control group （P〈0.05）. 2 year survival rate of the patients in the observation group was higher than that of the control group （P〈0.05）. Conclusion Oxaliplatin combined with epirubicin is effective and safe for patients with HCC, it＇ s worthy of further investigation and clinical application.

关 键 词：介入治疗 原发性肝癌 临床疗效 安全性 

分 类 号：R735.7[医药卫生—肿瘤]